<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Astellas Pharma Inc. — News on 6ix</title>
<link>https://6ix.com/company/astellas-pharma-inc</link>
<description>Latest news and press releases for Astellas Pharma Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 13 May 2026 13:19:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/astellas-pharma-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d6211cbeedb30cb6fc29e5.webp</url>
<title>Astellas Pharma Inc.</title>
<link>https://6ix.com/company/astellas-pharma-inc</link>
</image>
<item>
<title>Japan Regenerative Medicine Market Trends and Forecasts to 2035 Featuring Astellas Pharma, Fujifilm, JCR Pharmaceuticals, Sumitomo Pharma, Takeda, and Terumo</title>
<link>https://6ix.com/company/astellas-pharma-inc/news/japan-regenerative-medicine-market-trends-and-forecasts-to-2035-featuring-astellas-pharma-fujifilm-jcr-pharmaceuticals-sumitomo-pharma-takeda-and-terumo</link>
<guid isPermaLink="true">https://6ix.com/company/astellas-pharma-inc/news/japan-regenerative-medicine-market-trends-and-forecasts-to-2035-featuring-astellas-pharma-fujifilm-jcr-pharmaceuticals-sumitomo-pharma-takeda-and-terumo</guid>
<pubDate>Wed, 13 May 2026 13:19:00 GMT</pubDate>
<description>Japan's regenerative medicine market offers opportunities driven by an aging population, progressive regulations, and demand for novel therapies targeting chronic and cosmetic conditions. Innovations in stem cell and gene-editing technologies, alongside robust R&D investments and clinical collaborations, further bolster growth potential.Dublin, May 13, 2026 (GLOBE NEWSWIRE) -- The "Japan Regenerative Medicine Market - Distribution by Type of Product, Type of Therapeutic Area, End User and Key Ge</description>
</item>
<item>
<title>IZERVAY® (avacincaptad pegol intravitreal solution) Demonstrated Increased Probability of Maintaining Driving Eligibility in Geographic Atrophy Patients</title>
<link>https://6ix.com/company/astellas-pharma-inc/news/izervayr-avacincaptad-pegol-intravitreal-solution-demonstrated-increased-probability-of-maintaining-driving-eligibility-in-geographic-atrophy-patients</link>
<guid isPermaLink="true">https://6ix.com/company/astellas-pharma-inc/news/izervayr-avacincaptad-pegol-intravitreal-solution-demonstrated-increased-probability-of-maintaining-driving-eligibility-in-geographic-atrophy-patients</guid>
<pubDate>Tue, 12 May 2026 13:00:00 GMT</pubDate>
<description>Astellas Pharma US, Inc. (Head of US Commercial: Michael Petroutsas, "Astellas"), today announced results from a post hoc analysis of the GATHER1 and GATHER2 pivotal studies, showing treatment with IZERVAY reduced the risk of progressing to loss of driving eligibility compared with sham over 24 months in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The findings, presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeti</description>
</item>
<item>
<title>Astellas to Highlight New Findings for Geographic Atrophy at ARVO 2026 Annual Meeting</title>
<link>https://6ix.com/company/astellas-pharma-inc/news/astellas-to-highlight-new-findings-for-geographic-atrophy-at-arvo-2026-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/astellas-pharma-inc/news/astellas-to-highlight-new-findings-for-geographic-atrophy-at-arvo-2026-annual-meeting</guid>
<pubDate>Thu, 30 Apr 2026 13:00:00 GMT</pubDate>
<description>Astellas Pharma US, Inc. (Head of US Commercial: Michael Petroutsas, "Astellas") today announced new research insights for geographic atrophy (GA) that will be presented at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO), May 3-7, Denver, Colorado.</description>
</item>
<item>
<title>U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility</title>
<link>https://6ix.com/company/astellas-pharma-inc/news/us-fda-grants-priority-review-to-sbla-for-padcevtm-keytrudar-as-perioperative-treatment-for-muscle-invasive-bladder-cancer-regardless-of-cisplatin-eligibility-1</link>
<guid isPermaLink="true">https://6ix.com/company/astellas-pharma-inc/news/us-fda-grants-priority-review-to-sbla-for-padcevtm-keytrudar-as-perioperative-treatment-for-muscle-invasive-bladder-cancer-regardless-of-cisplatin-eligibility-1</guid>
<pubDate>Mon, 20 Apr 2026 10:45:00 GMT</pubDate>
<description>Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental Biologics License Application (sBLA) for perioperative (before and after surgery) PADCEV™ (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, in combination with the PD-1 inhibitor Keytruda® (pembrolizumab) or Keytruda QLEX™ (pembrolizumab and berahyaluronidase alfa-pmp</description>
</item>
<item>
<title>Dyno Therapeutics Announces Capsid License Exercised by Astellas for Skeletal Muscle-Targeted Gene Delivery, Validating AI-Powered Technology for Biological Sequence Design</title>
<link>https://6ix.com/company/astellas-pharma-inc/news/dyno-therapeutics-announces-capsid-license-exercised-by-astellas-for-skeletal-muscle-targeted-gene-delivery-validating-ai-powered-technology-for-biological-sequence-design</link>
<guid isPermaLink="true">https://6ix.com/company/astellas-pharma-inc/news/dyno-therapeutics-announces-capsid-license-exercised-by-astellas-for-skeletal-muscle-targeted-gene-delivery-validating-ai-powered-technology-for-biological-sequence-design</guid>
<pubDate>Wed, 08 Apr 2026 12:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., April 08, 2026--Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced that Astellas Pharma Inc. (TSE: 4503) has exercised its option to license a novel adeno-associated virus (AAV) capsid engineered for therapeutic delivery to skeletal muscle. This is the first capsid licensed from the companies’ research collaboration announced in December 2021, marking Dyno's first l</description>
</item>
<item>
<title>PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer</title>
<link>https://6ix.com/company/astellas-pharma-inc/news/padcevtm-keytrudar-cuts-risk-of-recurrence-or-death-by-nearly-50percent-in-cisplatin-eligible-muscle-invasive-bladder-cancer-1</link>
<guid isPermaLink="true">https://6ix.com/company/astellas-pharma-inc/news/padcevtm-keytrudar-cuts-risk-of-recurrence-or-death-by-nearly-50percent-in-cisplatin-eligible-muscle-invasive-bladder-cancer-1</guid>
<pubDate>Fri, 27 Feb 2026 15:00:00 GMT</pubDate>
<description>NEW YORK & TOKYO, February 27, 2026--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced positive results from the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for PADCEVTM (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda® (pembrolizumab), a PD-1 inhibitor, in patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy. Perioperative</description>
</item>
<item>
<title>Melodia Therapeutics Announces U.S. Patent Grant Covering MLD-151</title>
<link>https://6ix.com/company/astellas-pharma-inc/news/melodia-therapeutics-announces-us-patent-grant-covering-mld-151</link>
<guid isPermaLink="true">https://6ix.com/company/astellas-pharma-inc/news/melodia-therapeutics-announces-us-patent-grant-covering-mld-151</guid>
<pubDate>Wed, 25 Feb 2026 13:00:00 GMT</pubDate>
<description>Melodia Therapeutics AG today announced that the United States Patent and Trademark Office (USPTO) has granted a key U.S. patent covering a structurally novel DPP1 (Cathepsin C) inhibitor, currently developed as MLD-151 by Melodia Therapeutics and discovered by its partner, Alivexis, Inc., strengthening the intellectual property foundation supporting Melodia's lead development program.</description>
</item>
<item>
<title>Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer</title>
<link>https://6ix.com/company/astellas-pharma-inc/news/astellas-and-vir-biotechnology-announce-global-strategic-collaboration-to-advance-psma-targeting-pro-xtenr-dual-masked-t-cell-engager-vir-5500-for-the-treatment-of-prostate-cancer-1</link>
<guid isPermaLink="true">https://6ix.com/company/astellas-pharma-inc/news/astellas-and-vir-biotechnology-announce-global-strategic-collaboration-to-advance-psma-targeting-pro-xtenr-dual-masked-t-cell-engager-vir-5500-for-the-treatment-of-prostate-cancer-1</guid>
<pubDate>Mon, 23 Feb 2026 22:00:00 GMT</pubDate>
<description>Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced they have entered into a global strategic collaboration to advance VIR-5500, an investigational PRO-XTEN® dual-masked CD3 T-cell engager (TCE) targeting PSMA for the treatment of prostate cancer. The collaboration aims to accelerate the development of VIR-5500 and further strengthen Astellas' oncology pipeline and prostate cancer leadership.</description>
</item>
<item>
<title>Evinova Announces Strategic Collaborations with Astellas, AstraZeneca and Bristol Myers Squibb Advancing Its AI-Native Platform to Accelerate Global Clinical Development</title>
<link>https://6ix.com/company/astellas-pharma-inc/news/evinova-announces-strategic-collaborations-with-astellas-astrazeneca-and-bristol-myers-squibb-advancing-its-ai-native-platform-to-accelerate-global-clinical-development-2</link>
<guid isPermaLink="true">https://6ix.com/company/astellas-pharma-inc/news/evinova-announces-strategic-collaborations-with-astellas-astrazeneca-and-bristol-myers-squibb-advancing-its-ai-native-platform-to-accelerate-global-clinical-development-2</guid>
<pubDate>Wed, 18 Feb 2026 15:10:00 GMT</pubDate>
<description>BAAR, Switzerland, February 18, 2026--Evinova announces strategic collaborations with Astellas, AstraZeneca and Bristol Myers Squibb advancing its AI-native platform</description>
</item>
<item>
<title>VYLOY™ (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses</title>
<link>https://6ix.com/company/astellas-pharma-inc/news/vyloytm-zolbetuximab-plus-chemotherapy-associated-with-enhanced-survival-outcomes-when-common-adverse-events-are-effectively-managed-according-to-new-ad-hoc-analyses</link>
<guid isPermaLink="true">https://6ix.com/company/astellas-pharma-inc/news/vyloytm-zolbetuximab-plus-chemotherapy-associated-with-enhanced-survival-outcomes-when-common-adverse-events-are-effectively-managed-according-to-new-ad-hoc-analyses</guid>
<pubDate>Thu, 08 Jan 2026 15:30:00 GMT</pubDate>
<description>Astellas Pharma U.S., Inc. (Head of US Commercial: Mike Petroutsas, "Astellas") today announced the publication of exploratory ad hoc analyses from the combined Phase 3 SPOTLIGHT (NCT03504397) and GLOW (NCT03653507) studies in patients with HER2-negative, CLDN18.2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma in ESMO Open, characterizing the management of adverse events on treatment adherence and efficacy of VYLOY (zolbetuximab) plus chemotherapy and evaluating stra</description>
</item>
<item>
<title>Astellas to Present at 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/astellas-pharma-inc/news/astellas-to-present-at-44th-annual-jp-morgan-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/astellas-pharma-inc/news/astellas-to-present-at-44th-annual-jp-morgan-healthcare-conference</guid>
<pubDate>Tue, 06 Jan 2026 23:30:00 GMT</pubDate>
<description>Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced it will present at the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15, 2026, in San Francisco, Calif. As a global leader in life sciences, Astellas will use this premier platform to highlight its key strategic focuses and the tangible progress achieved to date in support of delivering long-term impact for patients, partners, and shareholders.</description>
</item>
<item>
<title>PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility</title>
<link>https://6ix.com/company/astellas-pharma-inc/news/padcevtm-plus-keytrudar-significantly-improves-survival-for-patients-with-muscle-invasive-bladder-cancer-regardless-of-cisplatin-eligibility</link>
<guid isPermaLink="true">https://6ix.com/company/astellas-pharma-inc/news/padcevtm-plus-keytrudar-significantly-improves-survival-for-patients-with-muscle-invasive-bladder-cancer-regardless-of-cisplatin-eligibility</guid>
<pubDate>Wed, 17 Dec 2025 11:45:00 GMT</pubDate>
<description>Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced positive topline results from an interim analysis of the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for PADCEV™ (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda® (pembrolizumab), a PD-1 inhibitor. This pivotal study is evaluating the combination as neoadjuvant and adjuvant treatment (before and after surgery) vers</description>
</item>
<item>
<title>Autobahn Labs Forms Strategic Partnership with Astellas to Accelerate Academic Discoveries into New Medicines</title>
<link>https://6ix.com/company/astellas-pharma-inc/news/autobahn-labs-forms-strategic-partnership-with-astellas-to-accelerate-academic-discoveries-into-new-medicines</link>
<guid isPermaLink="true">https://6ix.com/company/astellas-pharma-inc/news/autobahn-labs-forms-strategic-partnership-with-astellas-to-accelerate-academic-discoveries-into-new-medicines</guid>
<pubDate>Thu, 11 Dec 2025 12:30:00 GMT</pubDate>
<description>PALO ALTO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Autobahn Labs (“Autobahn”), a venture studio focused on transforming high-potential academic science into investable drug discovery and development programs, announced today a strategic partnership with global life sciences company Astellas Pharma Inc. (“Astellas”). The collaboration seeks to advance academic research and discoveries into novel therapeutics, providing Astellas’ Innovation Lab and Oncology Research units with integrated visibil</description>
</item>
<item>
<title>Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium</title>
<link>https://6ix.com/company/astellas-pharma-inc/news/astellas-to-present-new-clinical-data-across-its-gastrointestinal-cancers-portfolio-at-2026-asco-gi-cancers-symposium</link>
<guid isPermaLink="true">https://6ix.com/company/astellas-pharma-inc/news/astellas-to-present-new-clinical-data-across-its-gastrointestinal-cancers-portfolio-at-2026-asco-gi-cancers-symposium</guid>
<pubDate>Wed, 10 Dec 2025 23:30:00 GMT</pubDate>
<description>Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced it will present data on potential treatments for pancreatic and gastric/gastroesophageal junction (G/GEJ) cancer at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium taking place January 8-10, 2026 in San Francisco, California. Highlights include a late-breaking oral presentation of cohort results from the Phase 2 ILUSTRO study of first-line zolbetuximab in c</description>
</item>
<item>
<title>Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting</title>
<link>https://6ix.com/company/astellas-pharma-inc/news/astellas-to-present-new-data-on-xospatatm-gilteritinib-across-the-flt3m-aml-disease-continuum-at-ash-2025-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/astellas-pharma-inc/news/astellas-to-present-new-data-on-xospatatm-gilteritinib-across-the-flt3m-aml-disease-continuum-at-ash-2025-annual-meeting</guid>
<pubDate>Fri, 05 Dec 2025 13:00:00 GMT</pubDate>
<description>Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that new data evaluating XOSPATA™ (gilteritinib) across FMS-like tyrosine kinase 3 mutation-positive (FLT3m+) acute myeloid leukemia (AML), including in relapsed or refractory (R/R), newly diagnosed and post-transplant maintenance settings, will be presented at the upcoming American Society of Hematology (ASH) Annual Meeting taking place from 6-9 December 2025 in Orlando, Fla.</description>
</item>
<item>
<title>U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer</title>
<link>https://6ix.com/company/astellas-pharma-inc/news/us-fda-approves-padcevr-plus-keytrudar-for-certain-patients-with-bladder-cancer-1</link>
<guid isPermaLink="true">https://6ix.com/company/astellas-pharma-inc/news/us-fda-approves-padcevr-plus-keytrudar-for-certain-patients-with-bladder-cancer-1</guid>
<pubDate>Fri, 21 Nov 2025 18:24:00 GMT</pubDate>
<description>NEW YORK & TOKYO, November 21, 2025--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate (ADC), in combination with the PD-1 inhibitor Keytruda® (pembrolizumab) or Keytruda QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), as neoadjuvant treatment and then continued after cystectomy</description>
</item>
<item>
<title>Astellas and the Internet's Favorite Grandma, Barbara 'Babs' Costello, Partner to Encourage Others to Get Ahead of Geographic Atrophy (GA)</title>
<link>https://6ix.com/company/astellas-pharma-inc/news/astellas-and-the-internets-favorite-grandma-barbara-babs-costello-partner-to-encourage-others-to-get-ahead-of-geographic-atrophy-ga</link>
<guid isPermaLink="true">https://6ix.com/company/astellas-pharma-inc/news/astellas-and-the-internets-favorite-grandma-barbara-babs-costello-partner-to-encourage-others-to-get-ahead-of-geographic-atrophy-ga</guid>
<pubDate>Thu, 23 Oct 2025 12:00:00 GMT</pubDate>
<description>Astellas Pharma US Inc. (TSE: 4503, Head of US Commercial: Michael Petroutsas, "Astellas"), maker of IZERVAY™ (avacincaptad pegol intravitreal solution), today announced a partnership with beloved grandmother and content creator, Barbara 'Babs' Costello (@BrunchWithBabs), to challenge the misconception that vision changes are simply a normal part of aging, while raising awareness about the signs, risk factors and treatment of geographic atrophy (GA), the advanced form of dry age-related macular</description>
</item>
<item>
<title>Astellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study</title>
<link>https://6ix.com/company/astellas-pharma-inc/news/astellas-presents-preliminary-real-world-veozahtm-fezolinetant-data-from-option-vms-phase-iv-observational-study</link>
<guid isPermaLink="true">https://6ix.com/company/astellas-pharma-inc/news/astellas-presents-preliminary-real-world-veozahtm-fezolinetant-data-from-option-vms-phase-iv-observational-study</guid>
<pubDate>Wed, 22 Oct 2025 12:00:00 GMT</pubDate>
<description>Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced new real-world preliminary data from the OPTION-VMS Phase IV, longitudinal, observational study, providing the first insights into the real-world use of fezolinetant. The data demonstrated statistically significant improvements in VMS bother related to menopause, statistically significant improvements in subjective and objective sleep outcomes and significant improvements in activity impairment includi</description>
</item>
<item>
<title>PADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer</title>
<link>https://6ix.com/company/astellas-pharma-inc/news/padcevtm-enfortumab-vedotin-ejfv-plus-keytrudar-pembrolizumab-sbla-granted-fda-priority-review-for-treatment-of-certain-patients-with-muscle-invasive-bladder-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/astellas-pharma-inc/news/padcevtm-enfortumab-vedotin-ejfv-plus-keytrudar-pembrolizumab-sbla-granted-fda-priority-review-for-treatment-of-certain-patients-with-muscle-invasive-bladder-cancer</guid>
<pubDate>Tue, 21 Oct 2025 23:30:00 GMT</pubDate>
<description>Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a supplemental Biologics License Application (sBLA) for PADCEV™ (enfortumab vedotin-ejfv) in combination with KEYTRUDA® (pembrolizumab) as a neoadjuvant treatment (before surgery) and then continued after radical cystectomy as adjuvant treatment (after surgery) for patients with muscle-invasive bladder cancer (MIBC) who are i</description>
</item>
<item>
<title>IZERVAY™ (avacincaptad pegol intravitreal solution) Showed Increased Benefit in Reducing Geographic Atrophy Progression Over Time and Consistent Long-Term Safety</title>
<link>https://6ix.com/company/astellas-pharma-inc/news/izervaytm-avacincaptad-pegol-intravitreal-solution-showed-increased-benefit-in-reducing-geographic-atrophy-progression-over-time-and-consistent-long-term-safety</link>
<guid isPermaLink="true">https://6ix.com/company/astellas-pharma-inc/news/izervaytm-avacincaptad-pegol-intravitreal-solution-showed-increased-benefit-in-reducing-geographic-atrophy-progression-over-time-and-consistent-long-term-safety</guid>
<pubDate>Sun, 19 Oct 2025 23:30:00 GMT</pubDate>
<description>Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the first results from the open-label extension trial of the Phase 3 GATHER2 study, which demonstrated monthly treatment with IZERVAY™ (avacincaptad pegol intravitreal solution) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) continued to reduce GA lesion growth for up to 3.5 years, with earlier intervention resulting in greater protection of retinal tissue</description>
</item>
</channel>
</rss>